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ElderlyBackground and purpose: Describe the survival rates and distribution of events on competing failure types
in vulvar carcinoma after treatment with chemoradiation (CRT) or radiation (RT) alone.
Material and methods: We included patients with vulvar carcinoma treated with CRT or RT between 2009
and 2014. Survival was estimated using the Kaplan-Meier method. We performed a competing risk anal-
ysis and included five competing events: loco-regional failure (LRF), distant metastasis, LRF plus distant
metastasis, and death without evidence of disease, with the remaining patients denoted alive without
evidence of disease.
Results: 87 patients were treated. Progression free survival (PFS) and overall survival (OS) at 3 years were
40% and 57%, respectively. 41.3% of patients relapsed, most often loco-regionally. We saw significantly
worse PFS and OS for patients older than 68 (p = 0.011/p = 0.010) and for patients treated with definitive
RT (p = 0.004/p = 0.005). Competing risk analysis showed increased risk of LRF, and that death was most
often related to vulvar cancer. Death without disease recurrence was less frequent, even in the elderly.
Conclusions: LRF was the most common event. PFS and OS were inferior for elderly patients and patients
treated definitively. A better understanding of these differences may be used to define risk adapted treat-
ment strategies.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Vulvar cancer is a rare gynecological malignancy, annually
affecting 2–3 per 100,000 women worldwide [1]. In Denmark,
the incidence is 80–100 per year, accounting for approximately
0.5% of all cancers in women [2]. The majority of vulvar cancers
are squamous cell carcinomas (SCC) (76%) [3]. Vulvar cancer
mainly affects elderly women with a median age of 65–70 years.
During the past decades, the incidence of vulvar cancer has been
increasing, with a trend of younger women under the age of 60
being affected.
Due to the lack of randomized trials and to the low incidence of
vulvar cancer, many questions regarding treatment remain unan-
swered. Surgery is still the main treatment modality for vulvar can-
cer, but radiation (RT) also has an important role in management.
RT is typically delivered either as an adjuvant to surgery or as a
definite modality typically in conjunction with chemotherapy.
The optimal radiation dose prescription strategy is disputed, andmany treatment decisions are guided from clinical trials of
cervical- and anal cancer in the absence of sufficient vulvar cancer
research [4,5].
The risk of recurrence is correlated to tumor size, lymph node
involvement, and vascular invasion [3,6], and, unfortunately,
recurrence inside the radiation field is not uncommon. Due to
the rarity of this disease, knowledge of the pattern of loco-
regional failure after RT is limited.
We describe the fate of vulvar carcinoma patients after treat-
ment with chemoradiation (CRT) or RT in a large single institution
series. In particular we investigated the competing risks of death
from other causes, local and distant failure.Materials and methods
At the Department of Oncology, Rigshospitalet, Copenhagen
University Hospital, Denmark, we searched the patient registry
for referrals with ICD-10 diagnostic codes DC51-529. We excluded
patients with cancer of the clitoris and patients with vaginal cancer
and retrospectively reviewed the medical records of the remaining
patients with vulvar cancer. Patient data including medical history,
patient characteristics, tumor type, histopathological information,
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recurrence location, disease and survival status were obtained
from hospital records and registered.
For the primary staging procedure, patients were assessed by
both gynecologists and clinical oncologists at diagnosis and later
assessed by the multidisciplinary team of gynecologists, radiolo-
gists, pathologists and clinical oncologists in order to determine
the best treatment option for the individual patient. All patients
had CT, FDG PET-CT or MRI scans performed for diagnostic pur-
poses. Patients were staged according to the system of the Interna-
tional Federation of Gynecology and Obstetrics (FIGO). The primary
treatment was surgery if possible. Patients who underwent surgery
with positive margins or positive lymph nodes were referred to
adjuvant RT and thus included in this series, as were patients with
medically inoperable tumors referred for definitive RT.
RT was planned and delivered as follows: FDG PET-CT was used
for treatment planning unless contraindicated. The FDG PET-CT
was merged into the treatment planning system. Target volumes
were delineated following department guidelines: Nuclear Medi-
cine Physicians delineated FDG-PET avid volumes (GTV-PET), radi-
ologists with oncologists delineated gross tumor volumes (GTV)
and oncologists delineated the clinical target volumes (CTV). Plan-
ning target volumes (PTV) were produced by adding a margin of
7 mm to CTV. In patients with no macroscopic disease, only CTV
was delineated. The whole vulva was always included in the CTV,
if vulva had to be irradiated. If there was metastatic disease in
the nodes, the next nodal region was included in the CTV e.g. if
patients had metastatic disease in the superficial inguinal lymph
nodes, the deep inguinofemoral lymph nodes and lower half of
the external iliac lymph nodes were included in the CTV. Further-
more, the nodal CTV included gross tumor of nodes with a 1 cm
margin. See Table 1 for average volumes and dose coverage of
the delineated regions. Adjuvant or definitive RT was delivered as
external-beam RT to the vulva and/or inguinal nodal regions.
Patients were treated with either IMRT or Volumetric Modulated
Arc Therapy (VMAT). Prescribed dose was 60–64 Gy (2 Gy per frac-
tion) to the GTV for patients with macroscopic disease at the time
of treatment, with 50 Gy to regions without macroscopic involve-
ment, delivered as simultaneous integrated boost. For patients
without macroscopic disease, the prescribed dose was 46–
50.5 Gy (usually 1.8–2 Gy per fraction according to guidelines,
but two patients received 1.6 Gy/fraction). For patients deemed
fit for chemotherapy, concomitant cisplatin was administered
weekly 40 mg/mm2 with an upper limit to the total cisplatin dose
of 70 mg. Neoadjuvant or adjuvant chemotherapy is not a standard
of care according to department guidelines.
First follow-up visit after end of RT was at 12 weeks. Subse-
quent follow-up visits were with 3–4 months interval for 5 years.
If a patient at the time of RT planning had macroscopic disease
in the nodal area, first follow-up at 12 weeks included an FDGTable 1
Planning target volumes definitions, median target volumes and dose.
Volumes Definition Dose Adjuvant RT (median tar
GTV-PET FDG-PET avid volumes 64 Gy 3 (1–30)
GTV642 All GTV volumes prescribed 64 Gy 64 Gy 2 (1–342)3
PTV64 All PTV volumes prescribed 64 Gy 64 Gy 62 (10–663)
CTV50 All CTV volumes prescribed 50 Gy 50 Gy 821 (71–3704)
Volumes Definition Dose Adjuvant RT (median do
D98% GTV644 Given dose to 98% of GTV64 64 Gy 64.1 Gy (61.3–66.8)
D98% CTV50 Given dose to 98% of CTV50 50 Gy 48.8 Gy (43.1–53.4)
One patient was excluded from the entire analysis. The patient was treated with electro
1 Patients without the target volume/dose in question were excluded in the analyses
2 One patient was excluded from the GTV64 volume analysis since the boost dose wa
3 GTV in the adjuvant setting may include the entire remaining vulva in case of posit
4 For patients without GTVs, only CTVs are reported.PET-CT scan. If patients relapsed after RT, the multidisciplinary
team assessed them once again, in order to determine manage-
ment of the disease including possible post-radiation surgical
resection and/or chemotherapy. Patients with post-radiation treat-
ment failure were offered surgical resection if possible. If the recur-
rence was unresectable or the patients had disseminated disease,
they were offered palliative chemotherapy and/or RT. Patients
not eligible for resection and CRT were referred to palliative care
units.
The endpoints in our study were progression free survival (PFS),
overall survival (OS), time to local recurrence, distant recurrence or
simultaneous local and distant recurrence.
PFS was defined as the interval from the date of RT start to the
date of recurrence of the disease, death from any cause or last
follow-up (LFU) whichever came first. OS was defined as the inter-
val from the date of RT start to the date of death due to any cause.
We used a cut off in January 2015 for the OS analysis of the whole
series. Survival after a recurrence following RT or CRT was ana-
lyzed separately with a cut off in May 2015. Relapse date was
defined as the date of documentation of conclusive relapse i.e.
relapse determined unequivocally by either pathologist, clinical
oncologist or radiologist. For patients with recurrences, OS was
defined as the interval from the date of relapse to the date of death
due to any cause.
The data were analyzed using IBM SPSS statistics version 22.
Survival rates were calculated using the Kaplan-Meier method.
Comparisons were made using the log-rank test and a 2-sided
p-value of 0.05was considered significant. Additionallywe performed
Cox proportional hazardsmodeling of the impact of age on a contin-
uous scale. Cox regression was used to perform the univariate and
multivariate analysis, stratifying for adjuvant versus definitive
therapy. Age, tumor stage, use of cisplatin and primary vs. recurrent
disease were entered as prioritized covariables. We performed
competing risk analysis using the statistical software R version
3.1.2 and the CMPRSK package [7]. We included the following five
competing events in our analysis: loco-regional recurrence, distant
metastasis, loco-regional recurrence plus distant metastasis, and
death without evidence of disease, with the remaining patients
denoted alive with no evidence of disease.
The study was approved by The Danish Data Protection Agency
(approval No. 30-1322) and The Danish Health and Medicines
Authority (approval No. 3-3013-893/1).Results
Our searchproduced160patientswith thepreviouslymentioned
ICD-10 codes treated at the Department of Oncology, Rigshospitalet
between January 2009 and October 2014. 124 patients had con-
firmed vulvar cancer. In total, 37 patients were excluded – seeget volume, cm3 (range))1 Definitive RT (median target volume, cm3 (range))1
17.5 (3–232)
105.5 (5–320)
488.5 (54–1036)
1157 (242–2685)
se, Gy (range))1 Definitive RT (median dose, Gy (range))1
62.9 Gy (62.3–65.4)
49.2 Gy (48.1–50.9)
n fields that could not be reconstructed.
for median target volumes/dose.
s only 60 Gy.
ive surgical margins.
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with RT +/ chemotherapy with intent to cure. All 87 patients had
SCC of the vulva. Concomitant cisplatin was administered to 61
patients. Patient, tumor, treatment and recurrence characteristics
are shown in Table 2.
Lymph node status of the patients is presented in detail in
Table 2. Lymph nodes were left unresected either because the
nodes were unresectable, the primary tumor was unresectable
and therefore patients did not undergo any surgery, or patients
were not healthy enough to undergo major surgery. A few patients
had new FDG-avid nodes on the planning PET-CT scan, which were
then treated with RT. For the patients who underwent surgery
(n = 68), vascular invasion was seen in only four cases.
Themedian follow-up timewas 29 months (range 4–69 months)
calculated as median time to censoring in patients without events.
Median time to recurrence or death in the 42 patients experiencing
these events was 7.4 months (range 2–31 months). Response was
assessed at thefirst follow-up visit after the end of treatment. A total
of 64 patients had a complete response based on clinical examina-
tion possibly supplemented by FDGPET-CT (n = 22). Fifteen patients
had progressive disease; of these, one had distantmetastases, seven
failed loco-regionally, and seven had both distant metastases and
loco-regional recurrences. Five patients had suspected residual dis-
ease at the time of first follow-up, which was later confirmed. FourFig. 1. Flowchart of the ideof those patients failed loco-regionally, and one had both distant
metastases and loco-regional disease. Two patients were lost to
follow-up, and one patient died before her first appointment,
though all 87 patients are included in the survival analysis as OS
data is extracted from the Danish Civil Registration System.
For the entire series, PFS and OS rates at 1 year were 64% (95%
CI: 54 to 74) and 81% (95% CI: 73 to 89) and at 3 years 40% (95%
CI: 27 to 53) and 57% (95% CI: 44 to 70), respectively. We found
no significant difference in PFS and OS between patients with a pri-
mary tumor at the time of diagnosis and patients with recurrent
disease referred for curative CRT; Patients with a primary tumor
had 3 years PFS of 42% (95% CI: 27 to 57) compared to 32% (95%
CI: 6 to 58%) for patients with recurrent disease (p = 0.533). Simi-
larly we saw no difference in OS between the two groups
(p = 0.752).
The median age of the included patients was 68 years. For
patients 68 years compared to patients >68 years, PFS rates at
1 year were 71% (95% CI: 57 to 85) vs. 56% (95% CI: 41 to 71) and
at 3 years 58% (95% CI: 40 to 76) vs. 22% (95% CI: 6 to 38)
(p = 0.011). OS rates at 1 year were 86% (95% CI: 76 to 96) vs.
76% (95% CI: 63 to 89) and at 3 years 72% (95% CI: 56 to 88) vs.
40% (95% CI: 22 to 58) (p = 0.010) – see Fig. 2. We see the same
dependence of age when treated as a continuous variable in the
Cox proportional hazards model, HR = 1.44 (95% CI: 1.1 to 1.88)ntification of patients.
Table 2
Patient, tumor, treatment and recurrence characteristics.
Variables Adjuvant
RT
Definitive
RT
All recurrence
locations
Loco-regional
recurrences
Distant
metastases
Loco-regional + distant
metastases
Total no. of patients n = 68 n = 19 n = 36 n = 22 n = 2 n = 12
Age (years)
median
range
66.5
34–88
70
44–88
70
39–88
72
53–88
64.5
52–77
68.5
39–77
Tumor type
primary
recurrence
57
11
12
7
26
10
16
6
2
0
8
4
Tumor stage (FIGO)
II
IIIA
IIIB
IIIC
IVA
recurrence
12
26
5
14
0
11
2
2
0
2
6
7
3
8
3
9
3
10
3
5
3
3
2
6
0
1
0
1
0
0
0
2
0
5
1
4
Treatment given (RT+/ cisplatin)
adjuvant
definitive
- - 24
12
15
7
2
0
7
5
Positive margins
yes
no
n/a (no surgery/only groin
surgery)
50
17
1
-
-
19
18
6
12
11
4
7
1
1
0
6
1
5
Vascular invasion
yes
no
n/a*
4
63
1
-
-
19
1
23
12
0
15
7
1
1
0
0
7
5
Node resection
resected
not resected
no positive nodes**
62
3
3
3
13
3
23
10
3
14
5
3
2
0
0
7
5
0
Pathologically positive nodes
yes***
no
n/a
49
13
6
8
0
11
26
2
8
13
2
7
2
0
0
11
0
1
Extracapsular spread
yes
no
n/a
15
47
6
1
2
16
8
15
13
3
11
8
1
1
0
4
3
5
Chemotherapy
cisplatin (5–6 cycles)
cisplatin (1–4 cycles)
none
34
17
17
8
2
9
13
10
13
8
4
10
1
0
1
4
6
2
Radiation dose
40 Gy****
46–50.5 Gy
60 Gy
1
43
24
0
0
19
0
11
25
0
6
16
0
2
0
0
3
9
Notes: RT = radiation therapy.
* No surgery/biopsy only. Biopsies only without vascular invasion.
** No positive nodes on imaging or histologically.
*** Some patients had lymph node biopsy only with a positive result, but the nodes were left unresected.
**** Patient did not complete planned course of 50 Gy (refusal). The patient is alive without evidence of disease.
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2.06) per 10 years increase in age for OS.
A total of 36 patients relapsed after treatment. Twenty-two
patients had loco-regional recurrences, two patients had distant
metastases as first sign of recurrence, and 12 patients had simulta-
neously detected loco-regional and distant relapse. The risk of pro-
gression was substantial for elderly patients and for patients
treated definitively, and the risk decreased with the use of con-
comitant chemotherapy – see Fig. 2. Also, patients who had nodes
left unresected, and patients who had nodes with extra capsular
spread were at a higher risk of progression – see Table 2.
Cumulative incidence plots in the competing risk model are
shown in Fig. 3. Patients above 68 years and patients treated with
definitive RT were at risk of especially loco-regional recurrences
(Gray’s test for difference in local control: p = 0.053 (age) and
p = 0.146 (adjuvant vs. definitive RT)). Survival after a recurrence
following CRT was poor as shown in Fig. 4. Cox regression resultsare given in Table 3 including age, use of cisplatin, tumor stage
and primary vs. recurrent disease. As a note of caution, in this ret-
rospective analysis the HR for use of cisplatin includes patient
selection due to general health condition.Discussion
A substantial amount of patients treated for vulvar carcinoma
experience a recurrence after treatment. Our study showed a
recurrence rate of 41.3%. This is in accordance with Maggino
et al. [6] (37.3%) and Mak et al. [8] (45.4%). Absolute rates of recur-
rence in an individual institution will clearly depend on the selec-
tion of patients for CRT or RT.
The use of CRT to treat patients with vulvar carcinoma has been
adopted from trials on anal- and cervical cancer [4,5]. Some smal-
ler studies and a few phase II trials have indicated CRT to be
Fig. 2. Progression free survival (left) and overall survival (right) depending on age (A + B), administration of concomitant chemotherapy (C + D) and type of radiotherapy
(E + F).
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Fig. 3. Cumulative incidence plots in the competing risk model. Mutually exclusive endpoints add up to 100%. Probability of being alive without evidence of disease is the
white area at the top. Note that loco-regional recurrence and loco-regional recurrence plus distant metastases are the main reasons for the deteriorated outcome in elderly
patients. Gray’s test for difference in local control in elderly vs. younger patients: p = 0.053. Gray’s test for difference in local control between patients treated with adjuvant
and definitive radiotherapy: p = 0.146.
Fig. 4. Overall survival after a recurrence.
Table 3
Cox regression stratified for adjuvant versus definitive therapy.
Variables Univariate Multivariate
Progression free survival
Adjuvant vs. definitive
therapy
Stratified Stratified
Age* HR = 1.40 [1.07–1.82]
p = 0.014
HR = 1.29 [0.95–1.8]
p = 0.11
Cisplatin (yes vs. no) HR = 0.5 [0.3–1.0]
p = 0.055
HR = 0.8 [0.4–1.7]
p = 0.51
FIGO tumor stage** HR = 1.2 [0.9–1.3]
p = 0.50
HR = 1.2 [0.9–1.6]
p = 0.22
Primary vs. recurrent
disease
HR = 0.8 [0.4–1.6]
p = 0.50
HR = 0.5 [0.2–1.6]
p = 0.25
Overall survival
Adjuvant vs. definitive
therapy
Stratified Stratified
Age* HR = 1.48 [1.07–2.02]
p = 0.016
HR = 1.20 [0.83–1.74]
p = 0.35
Cisplatin (yes vs. no) HR = 0.3 [0.2–0.7]
p = 0.004
HR = 0.4 [0.2–1.0]
p = 0.061
FIGO tumor stage** HR = 1.1 [0.9–1.4]
p = 0.37
HR = 1.3 [0.9–1.8]
p = 0.13
Primary vs. recurrent
disease
HR = 1.0 [0.4–2.2]
p = 0.92
HR = 0.4 [0.1–1.4]
p = 0.16
In progression free survival analysis, death of any cause or progression is treated as
events.
* Age as continuos covariable. HR given per 10 year increase.
** FIGO stage I-IV as continuos covariable.
C.S. Vorbeck et al. / Clinical and Translational Radiation Oncology 5 (2017) 20–27 25
26 C.S. Vorbeck et al. / Clinical and Translational Radiation Oncology 5 (2017) 20–27effective in the treatment of vulvar cancer patients [8–13], but the
optimal treatment regime still remains to be found in order to
secure loco-regional control while keeping toxicity low. Our results
demonstrated improved outcome on PFS and OS in patients treated
with concomitant chemotherapy. However, this effect must be
expected to be biased in this retrospective analysis due to the
selection of patients deemed fit for treatment with chemotherapy.
The prescription of cisplatin is correlated to the age of the patient.
In the univariate analyses the two factors are separately analyzed
and both carry the entire signal and are significant or close to sig-
nificant on PFS and OS. In the multivariate analysis, they share part
of the overall effect (due to poor prognostic of age and omission of
cisplatin coincide in many of the patients) and both point esti-
mates go towards 1 compared to the univariate analyses. They
loose individual significance in the multivariate analyses, probably
also due to the limited sample size. It should be noted that the age
variable is the most robust of the two univariate predictors empha-
sizing that assessment of the true value of cisplatin prescription
requires randomization.
Inferior outcome in elderly patients is documented with signif-
icantly worse PFS and OS for elderly patients (Fig. 2) whether
assessed as older/younger than median or as a continuous variable
in univariate Cox regression. The competing risk analysis allows
subdivision of the events in PFS analysis in the competing failure
modes [14]. This analysis showed that elderly patients have
increased risk of all disease specific endpoints, especially loco-
regional failure. In other words, the inferior outcome of the elderly
patients is primarily disease related and not due to the patients
dying from non-cancerous courses. Treatment of elderly patients
with CRT can be challenging due to possible comorbidities and
the risk of treatment complications. Our results indicate that while
clinical decisions regarding the de-intensification of therapy for
frail patients are, of course, necessary, loco-regional recurrence
should still be expected to be the dominant cause of mortality in
these patients. Decreasing treatment intensity solely on the basis
of patient age is probably not a wise choice.
Part of the explanation for the difference in prognosis between
old and young could be related to a potential different biology of
the disease. Different risk factors for development of vulvar carci-
noma have been shown [15], and besides chronic skin diseases
such as lichen sclerosis, human papillomavirus (HPV) infection
also plays a role in the development of SCC of the vulva. The lit-
erature suggests two different pathways leading to SCC of the
vulva; an HPV-dependent and an HPV-independent pathway
[16,17]. The prognostic role of HPV infection still remains unclear,
as some studies have found no significant difference in prognosis
between HPV-positive and HPV-negative patients [18,19],
whereas others suggest improved survival in HPV-positive
patients [20,21]. The reason for the observed difference in progno-
sis between young and elderly in our series is, however, specula-
tion at present.
Vulvar cancer is a rare disease, but the centralization of treat-
ment in the Danish healthcare system has allowed the extraction
of data on 87 patients in the current single institution series. In
comparison, the included studies in a recently published system-
atic review [22] had a mean inclusion of seven patients. Stuckey
et al. [22] found a non-significant trend towards elderly patients
being more likely to die from intercurrent disease and from treat-
ment complications compared to non-elderly patient, but available
data did not allow proper survival data analysis. Survival obviously
decreases with age at diagnosis as death from intercurrent disease
increases with age. However, with proper survival analyses our
results still suggest that the inferior prognosis for the elderly
patients is vulvar cancer related. To overcome the rarity of the dis-
ease and to gain more statistical power, the optimal solution would
of course be to conduct multi-institutional studies, and theseshould put emphasis on improving loco-regional therapy to the
elderly and to patients treated definitively.
The retrospective nature of our study andwide inclusion criteria
required to obtain a meaningful sample size for analysis inevitably
lead to some heterogeneity in the patients studied, see Table 2, and
should be acknowledged as a limitation. However, the hypotheses
presented and proper (albeit descriptive) survival statistics are
important in this narrow field. Furthermore, treatment was quite
homogenous within the adjuvant and definitive groups; Depart-
ment protocol was in place, and patients were treated in a consis-
tent fashion. Subdividing patients further into smaller groups to
investigate different prognostic factors is unfortunately not statisti-
cally feasible, and a more detailed analysis of the pattern of failure
is beyond the scope of this article. However, our study does illus-
trate a clear pattern, with loco-regional recurrences being the most
frequent type of failure. Especially elderly patients and patients
treated definitively are at a substantial risk of loco-regional recur-
rence or synchronous loco-regional recurrence and distant metas-
tasis. The fact that the patients most often relapse locally within
the radiation field suggests room for improvement of the local ther-
apy, either in the form of development of improved surgical proce-
dures or more aggressive RT. Further systematic analyses of
recurrences after RT could hold a potential to investigate the use
ofmore targeted radiation dose prescription in the future, for exam-
ple using radiation dose painting [23,24].Conflict of interest statement
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